In:
Journal of Diabetes Investigation, Wiley, Vol. 3, No. 5 ( 2012-10), p. 464-467
Abstract:
This study was initiated to identify clinical and dietary parameters that predict efficacy of dipeptidyl peptidase‐4 inhibitors. A total of 72 untreated Japanese patients with type 2 diabetes who received DPP‐4 inhibitors (sitagliptin, alogliptin or vildagliptin) for 4 months were examined for changes of glycated hemoglobin (HbA 1c ) and body mass index (BMI), and self‐administered 3‐day food records, as well as serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). DPP‐4 inhibitors significantly reduced HbA 1c (before initiation of DPP‐4 inhibitors 7.2 ± 0.7%, 4 months after initiation of DPP‐4 inhibitors 6.7 ± 0.6% [paired t ‐test, P 〈 0.01 vs before]). Multiple regression analysis showed that changes of HbA 1c were significantly correlated with baseline HbA 1c, as well as estimated intake of fish. Furthermore, changes of HbA 1c were significantly correlated with serum levels of EPA ( r = −0.624, P 〈 0.01) and DHA ( r = −0.577, P 〈 0.01). HbA 1c reduction by DPP‐4 inhibitors is significantly correlated with estimated intake of fish and serum levels of EPA and DHA. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00214.x, 2012)
Type of Medium:
Online Resource
ISSN:
2040-1116
,
2040-1124
DOI:
10.1111/jdi.2012.3.issue-5
DOI:
10.1111/j.2040-1124.2012.00214.x
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2542077-X
Permalink